Nuwellis, Inc. (NUWE)
| Market Cap | 2.90M |
| Revenue (ttm) | 8.27M |
| Net Income (ttm) | -17.52M |
| Shares Out | 2.64M |
| EPS (ttm) | -25.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,545 |
| Open | 1.140 |
| Previous Close | 1.160 |
| Day's Range | 1.100 - 1.200 |
| 52-Week Range | 0.960 - 45.419 |
| Beta | 0.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About NUWE
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through specialty healthcare distributors in Au... [Read more]
Financial Performance
In 2025, Nuwellis's revenue was $8.27 million, a decrease of -5.38% compared to the previous year's $8.74 million. Losses were -$17.52 million, 64.9% more than in 2024.
Financial StatementsNews
Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter Technology
MINNEAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that t...
Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530 Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth ...
Nuwellis Announces Aquadex Software Update
MINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software up...
Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum
MINNEAPOLIS, April 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the re...
Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services
MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has...
Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory
Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region Strategic expansion of field coverage enhances hospital engagement and inc...
Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone
Pediatric footprint expands to 47 centers nationwide, including six of the nation's top 10 children's hospitals Pediatric footprint expands to 47 centers nationwide, including six of the nation's top ...
Nuwellis Completes Acquisition of Rendiatech
MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced ...
Nuwellis Earnings Call Transcript: Q4 2025
2025 saw a 5% revenue decline but operational strengthening, improved gross margins, and strategic focus on cardiorenal and pediatric markets. The company exited the EU, acquired Rendiatech, and ended the year with $1.2M cash and no debt.
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported f...
Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy
MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced ...
Nuwellis Appoints David A. McDonald and Martin J.
MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced t...
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced t...
Nuwellis Appoints Carisa Schultz as Chief Financial Officer
Schultz brings public company healthcare finance and medical technology experience to support Nuwellis' next phase of growth Schultz brings public company healthcare finance and medical technology exp...
Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on advancing precision cardiorenal care in critical car...
Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio Strategy
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced th...
Nuwellis Stock Surges 100% As $2 Microcap Beats Big Pharma In Infant Healthcare
Nuwellis Inc (NASDAQ: NUWE) stock is on fire. Shares of the tiny medical device maker surged more than 100% in pre-market trading Tuesday and were still up around 85% by 10 AM ET in early trading, as ...
Nuwellis Announces Changes to Board of Directors
MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced th...
Nuwellis Announces Issuance of New U.S. Patent Supporting Advanced Safety Design for Pediatric Extracorporeal Therapy
Patent issuance strengthens pediatric intellectual property portfolio and advances system-level safety design Patent issuance strengthens pediatric intellectual property portfolio and advances system-...
Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings
Findings reinforce Nuwellis' leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload. Findings reinforce Nuwellis' leadership in precision ultrafiltration for ...
Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S.
Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex cases Pediatric nephrology and cardiology teams continue to seek out Aquadex for sa...
Nuwellis Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue of $2.2M, a 6% year-over-year decrease, but 7% proforma growth excluding one-time and international impacts. Growth was led by heart failure and critical care, with new product launches and operational shifts supporting future margin expansion.
Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum
MINNEAPOLIS, MN, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing th...
Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian™ Pediatric System with Advanced Clamp Safety Technology
MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the c...
Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025
MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the c...